Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 11.87 +0.11 (+0.94%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Roivant Sciences Ltd < Previous 1 2 3 4 5 6 Next > Price Over Earnings Overview: Roivant Sciences October 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session October 03, 2024 Via Benzinga Organon, Howmet Aerospace And More: CNBC's 'Final Trades' October 03, 2024 On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade. Via Benzinga Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B September 18, 2024 Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2... Via Benzinga 4 Analysts Assess Roivant Sciences: What You Need To Know September 11, 2024 Via Benzinga Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer September 10, 2024 Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments. Via Benzinga Evaluating Roivant Sciences: Insights From 6 Financial Analysts June 18, 2024 Via Benzinga The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts May 31, 2024 Via Benzinga Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know April 22, 2024 Via Benzinga What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? September 09, 2024 Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the... Via Benzinga Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers August 29, 2024 Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. Via Investor's Business Daily ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 May 30, 2024 ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. Via InvestorPlace Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? May 22, 2024 BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million. Via Benzinga Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare May 07, 2024 Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. Via InvestorPlace Where Roivant Sciences Stands With Analysts March 25, 2024 Via Benzinga The Analyst Landscape: 4 Takes On Roivant Sciences February 14, 2024 Via Benzinga Roivant Sciences Earnings Preview February 12, 2024 Via Benzinga Assessing Roivant Sciences: Insights From 5 Financial Analysts January 02, 2024 Via Benzinga 3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 May 01, 2024 Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. Via InvestorPlace Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study April 02, 2024 Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure... Via Benzinga Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study April 02, 2024 The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira. Via Investor's Business Daily 10 Health Care Stocks Whale Activity In Today's Session March 29, 2024 Via Benzinga Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase March 27, 2024 Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading. Via Investor's Business Daily Analyst Ratings for Roivant Sciences December 12, 2023 Via Benzinga 5 Value Stocks In The Healthcare Sector February 19, 2024 Via Benzinga Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space January 12, 2024 The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. Via Investor's Business Daily Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations January 10, 2024 Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to Via Benzinga Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% December 21, 2023 Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in Via Benzinga FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session December 20, 2023 U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Earnings Scheduled For February 13, 2024 February 13, 2024 Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
